E0671 is developed by Eisai Co., Ltd..

What development phase is E0671 in?

E0671 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

E0671

Eisai Co., Ltd. · FDA-approved active Small molecule Quality 6/100

At a glance

Generic name	E0671
Sponsor	Eisai Co., Ltd.
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

E0671 CI brief — competitive landscape report
E0671 updates RSS · CI watch RSS
Eisai Co., Ltd. portfolio CI